Pipeline

Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics.

Indication

Product Candidate

Discovery

Ind enabling phase

Phase 1

Retinitis Pigmentosa

Genotype agnostic

RTx-015

Pre-IND

Other Inherited retinal degenerations

Choroideremia 
Stargardt’s disease

RTx-015

Discovery

Geographic Atrophy

RTX-021

Discovery